Time-resolved nanosecond imaging of the propagation of a corona-like plasma discharge in water at positive applied voltage polarity

International audienceThe present paper is an experimental study of a pulsed filamentary plasma discharge inside liquid water in pin to plane electrode configuration. Time resolved electrical and imaging diagnostics have been performed. The initiation and the propagation of the discharge have been studied for several experimental parameters. The propagation is continuous and is followed by reilluminations at low water conductivity. The measured propagation velocity of the plasma discharge is 30km/s for the secondary positive mode. This velocity was found to be surprisingly constant whatever the experimental parameters and especially as a function of the water conductivity

High energy electron transport in solids

With the addition of recent PW shots, the propagation of short-pulse laser generated electron beams have been studied using laser pulse energies from 30 J to 300 J, generating currents up to ∼15 MA in solid Al:Cu targets. This is ∼5% of the current that will be required in an ignition pulse. To this level, the current appears to simply scale with laser power, the propagation spread not change at all. The resistance of the aluminum does not seem to play a role in the propagation characteristics, though it might in setting the current starting parameters. We do find that at the highest currents parts of these targets reach temperatures high enough to modify the Cu-K2 emission spectrum rendering our Bragg imaging mirrors ineffective; spectrometers will be needed to collect data at these higher temperatures. © EDP Sciences

Effect of dynamic random leaks on the monitoring accuracy of home mechanical ventilators: a bench study

BACKGROUND: So far, the accuracy of tidal volume (VT) and leak measures provided by the built-in software of commercial home ventilators has only been tested using bench linear models with fixed calibrated and continuous leaks. The objective was to assess the reliability of the estimation of tidal volume (VT) and unintentional leaks in a single tubing bench model which introduces random dynamic leaks during inspiratory or expiratory phases. METHODS: The built-in software of four commercial home ventilators and a fifth ventilator-independent ad hoc designed external software tool were tested with two levels of leaks and two different models with excess leaks (inspiration or expiration). The external software analyzed separately the inspiratory and expiratory unintentional leaks. RESULTS: In basal condition, all ventilators but one underestimated tidal volume with values ranging between -1.5 ± 3.3% to -8.7% ± 3.27%. In the model with excess of inspiratory leaks, VT was overestimated by all four commercial software tools, with values ranging from 18.27 ± 7.05% to 35.92 ± 17.7%, whereas the ventilator independent-software gave a smaller difference (3.03 ± 2.6%). Leaks were underestimated by two applications with values of -11.47 ± 6.32 and -5.9 ± 0.52 L/min. With expiratory leaks, VT was overestimated by the software of one ventilator and the ventilator-independent software and significantly underestimated by the other three, with deviations ranging from +10.94 ± 7.1 to -48 ± 23.08%. The four commercial tools tested overestimated unintentional leaks, with values between 2.19 ± 0.85 to 3.08 ± 0.43 L/min. CONCLUSIONS: In a bench model, the presence of unintentional random leaks may be a source of error in the measurement of VT and leaks provided by the software of home ventilators. Analyzing leaks during inspiration and expiration separately may reduce this source of error

Superfluid fraction in an interacting spatially modulated Bose-Einstein condensate

At zero temperature, a Galilean-invariant Bose fluid is expected to be fully superfluid. Here we investigate theoretically and experimentally the quenching of the superfluid density of a dilute Bose-Einstein condensate due to the breaking of translational (and thus Galilean) invariance by an external 1D periodic potential. Both Leggett's bound fixed by the knowledge of the total density and the anisotropy of the sound velocity provide a consistent determination of the superfluid fraction. The use of a large-period lattice emphasizes the important role of two-body interactions on superfluidity

What is the remaining status of adaptive servo-ventilation? The results of a real-life multicenter study (OTRLASV-study). Adaptive servo-ventilation in real-life conditions

Backgrounds: As a consequence of the increased mortality observed in the SERVE-HF study, many questions concerning the safety and rational use of ASV in other indications emerged. The aim of this study was to describe the clinical characteristics of ASV-treated patients in real-life conditions. Methods: The OTRLASV-study is a prospective, 5-centre study including patients who underwent ASV-treatment for at least 1 year. Patients were consecutively included in the study during the annual visit imposed for ASV- reimbursement renewal. Results: 177/214 patients were analysed (87.57% male) with a median (IQ25–75) age of 71 (65–77) years, an ASV- treatment duration of 2.88 (1.76–4.96) years, an ASV-usage of 6.52 (5.13–7.65) hours/day, and 54.8% were previously treated via continuous positive airway pressure (CPAP). The median Epworth Scale Score decreased from 10 (6–13.5) to 6 (3–9) (p < 0.001) with ASV-therapy, the apnea-hypopnea-index decreased from 50 (38–62)/h to a residual device index of 1.9 (0.7–3.8)/h (p < 0.001). The majority of patients were classified in a Central-Sleep-Apnea group (CSA; 59.3%), whereas the remaining are divided into an Obstructive-Sleep-Apnea group (OSA; 20.3%) and a Treatment-Emergent-Central-Sleep-Apnea group (TECSA; 20.3%). The Left Ventricular Ejection Fraction (LVEF) was > 45% in 92.7% of patients. Associated comorbidities/etiologies were cardiac in nature for 75.7% of patients (neurological for 12.4%, renal for 4.5%, opioid-treatment for 3.4%). 9.6% had idiopathic central-sleep-apnea. 6.2% of the patients were hospitalized the year preceding the study for cardiological reasons. In the 6 months preceding inclusion, night monitoring (i.e. polygraphy or oximetry during ASV usage) was performed in 34.4% of patients, 25.9% of whom required a subsequent setting change. According to multivariable, logistic regression, the variables that were independently associated with poor adherence (ASV-usage ≤4 h in duration) were TECSA group versus CSA group (p = 0.010), a higher Epworth score (p = 0.019) and lack of a night monitoring in the last 6 months (p < 0.05). Conclusions: In real-life conditions, ASV-treatment is often associated with high cardiac comorbidities and high compliance. Future research should assess how regular night monitoring may optimize devices settings and patient management

Change in Sleep Quality Associated With Adaptive Servoventilation for Central Sleep Apnea: Six-Month Follow-Up of the Multicenter Nationwide French "Etude de Cohorte Observationnelle Multicentrique Française de Patients Ayant un Syndrome d'Apnées du Sommeil Central ou Combiné Avec SAS Central Prédominant, Traités par Ventilation Auto-Asservie (FACIL-VAA)" Cohort

Background: A large number of symptomatic individuals with central sleep apnea (CSA) in clinical practice have an indication for adaptive servoventilation (ASV) therapy. Research Question: What are the effects of ASV therapy on sleep quality and patient-reported outcome measures in patients with CSA across a range of devices and indications? Study Design and Methods: This prospective multicenter observational cohort study was conducted in France and enrolled participants from June 2017 through February 2020. Adults with predominant CSA at diagnosis or OSA with central events not controlled with CPAP who had an indication for ASV were eligible. Participants attended clinic visits at baseline and after 1, 3, 6, and 12 months of follow-up. The primary end point was the change in Pittsburgh Sleep Quality Index (PSQI) score from baseline to 6-month follow-up (evaluated using a Wilcoxon signed-rank test on paired data). Results: We included 526 individuals (median age, 69 years; 88.2% male). The indication for ASV included CSA with cardiovascular or neurologic cause (38.4%), treatment-emergent CSA (36.1%), idiopathic CSA (14.1%), or drug-induced CSA (11.4%). At the 6-month follow-up, study participants were using ASV for a median of 6.1 h/night. The median change in the PSQI score from baseline to 6 months in the overall study population was –1 (interquartile range, –3 to 0; P < .001), with significant results across all indications for ASV except for drug-induced CSA, where the median change was similar to the overall results, but did not achieve statistical significance (–1 [interquartile range, –2 to 1]; P = .0866). Overall, 65% of participants showed a ≥ 1-point improvement in the PSQI. Interpretation: In this study, individuals with a clinical indication for ASV therapy experienced improved sleep quality during real-world treatment, regardless of which ASV device was used. Clinical Trial Registry: ClinicalTrials.gov; No.: NCT02835638; URL: www.clinicaltrials.go